When was TAI Diagnostics founded?

TAI Diagnostics was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is TAI Diagnostics located?

TAI Diagnostics is headquartered in Milwaukee, United States. It is registered at Racine, Wisconsin.

Who is the current CEO of TAI Diagnostics?

Frank Langley of TAI Diagnostics.

How many employees does TAI Diagnostics have?

As of Dec 31, 2022, TAI Diagnostics has 30 employees, reflecting a 9% year-over-year decline in headcount.

Is TAI Diagnostics a funded company?

TAI Diagnostics is a funded company, having raised a total of $21.1M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 23, 2015.

When was the latest funding round of TAI Diagnostics?

TAI Diagnostics' latest funding was a $***** Series A round on Jun 28, 2018, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.02B in funding in 2026 to date.

Where does TAI Diagnostics rank among its competitors?

TAI Diagnostics ranks 64th amongst 163 active competitors, of which 55 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of TAI Diagnostics?

TAI Diagnostics' top competitors include Guardant Health, GRAIL and BillionToOne. Among them, GRAIL secured the most recent funding round in June, 2026.

TAI Diagnostics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of diagnostic solutions for transplant patients. Its flagship product is a non-invasive blood test that can be used to monitor if heart transplant patients are rejecting the new organ by measuring the levels of cell-free DNA originating from the transplanted organ in the patient's blood. Its founding team was previously involved with Ariosa Diagnostics, which was acquired by Roche.

Website: taidiagnostics.com
Registered Address: Racine, Wisconsin

Key Metrics

Founded Year

2013

Location

Milwaukee, United States

Stage

Series A

Total Funding

$21.1M in 2 rounds

Latest Funding Round

Series A, Jun 28, 2018, $*****

Investors

Venture Investors & 2 more

Ranked

64^th among 163 active competitors

Employee Count

30 as on Dec 31, 2022

Similar Companies

Guardant Health & 156 more

View TAI Diagnostics' full profile

TAI Diagnostics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
TAI DIAGNOSTICS CIN: 464742850 , United States, Active	Dec 26, 999	-	30 (As on Dec 31, 2019)	-

TAI Diagnostics has raised a total funding of $21.1M over 2 rounds. Its first funding round was on Oct 23, 2015. Its latest funding round was a Series A round on Jun 28, 2018 for $*****. 1 investor participated in its latest round. TAI Diagnostics has 3 institutional investors.

Here is the list of recent funding rounds of TAI Diagnostics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 28, 2018	4989551	Series A	4319422	4749717	9603342	3176478
Oct 23, 2015	2179942	Series A	4282534	4071464	Venture Investors	7847005

Access funding benchmarks and valuations. Sign up today!

View details of TAI Diagnostics's funding rounds and investors

TAI Diagnostics' employee count trend

TAI Diagnostics has 30 employees as of Dec 22. The total employee count is 9.0% lower than what it was in Dec 21. Here is TAI Diagnostics's employee count trend over the years:

Employee count trend for TAI Diagnostics

Uncover TAI Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TAI Diagnostics include Guardant Health, GRAIL and BillionToOne. Here is the list of Top 10 competitors of TAI Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
2nd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	69/100
3rd	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
4th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
5th	Scipher Medicine 2014, Waltham (United States), Series D	Provider of precision medicine based on liquid biopsy test	$233M	Northpond Ventures, Cowen & 14 others	65/100
6th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	64/100
7th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Orbimed & 19 others	64/100
8th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
9th	Naveris 2017, Waltham (United States), Acquired	Provider of blood tests for early cancer detection	$68.5M	Gurnet Point Capital, B-FLEXION & 3 others	60/100
10th	Codiak BioSciences 2015, Cambridge (United States), Public	Developer of exosome-based drugs and diagnostics for cancer treatment	$168M	Arch Venture Partners, Flagship Pioneering ... & 10 others	57/100
64th	TAI Diagnostics 2013, Milwaukee (United States), Series A	Provider of diagnostic solutions for transplant patients	$21.1M	United Therapeutics, Venture Investors & 1 others	38/100